Q-omics provides the consensus-scored TRDJ3 profile across patient tissues and cancer cell-line models. TRDJ3 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, TRDJ3 is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, TRDJ3 RNA expression shows 9,529 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCS, KIRC, and THYM as cancer lineages where TRDJ3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRDJ3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRDJ3 survival associations across molecular data types. TRDJ3 RNA expression shows survival associations in the most cancer types (15), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRDJ3 RNA expression–survival associations across cancer types. High TRDJ3 expression shows unfavorable associations in UCS, UVM, LGG and LUSC, but favorable associations in HNSC and GBM. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for TRDJ3 RNA expression.
This table summarizes TRDJ3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TRDJ3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRDJ3 shows lower tumor expression in LUSC and BLCA and higher tumor expression in KIRC and THCA. The KIRC box plot shows higher TRDJ3 RNA expression in tumor versus normal tissue (log2 FC = +0.321, t-test p < 0.001).
This table shows molecular features associated with TRDJ3 in patient tissues and cancer cell lines. In patient samples, TRDJ3 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
